Parkinsonian Syndromes

Also known as: Parkinsonian Syndrome / Parkinsonian syndromes / Parkinsonian Disorders / Parkinsonism / Hypokinetic-rigid syndrome

DrugDrug NameDrug Description
DB00363ClozapineA tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. [PubChem]
DB01075DiphenhydramineDiphenhydramine, also known commercially as Benadryl, is a first generation antihistamine that is used primarily for the treatment of seasonal allergies. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system. While its use in in allergies has largely fallen out of favour due to this sedative effect, diphenhydramine has been repurposed for use within many OTC (over the counter) cough-and-cold medications that have been marketed for "night time" use. Diphenhydramine is also used in combination with [DB14132] as the anti-nausea drug [DB00985] where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system [A1540]. Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid [A1539]. As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.
DB00387ProcyclidineA muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.
DrugDrug NameTargetType
DB00363ClozapineD(4) dopamine receptortarget
DB00363ClozapineHistamine H1 receptortarget
DB00363ClozapineD(2) dopamine receptortarget
DB00363ClozapineNeuron-specific vesicular protein calcyontarget
DB00363ClozapineHistamine H4 receptortarget
DB00363Clozapine5-hydroxytryptamine receptor 2Atarget
DB00363Clozapine5-hydroxytryptamine receptor 1Atarget
DB00363Clozapine5-hydroxytryptamine receptor 2Ctarget
DB00363ClozapineD(1A) dopamine receptortarget
DB00363ClozapineCytochrome P450 1A2enzyme
DB00363ClozapineCytochrome P450 2D6enzyme
DB00363ClozapineD(3) dopamine receptortarget
DB00363ClozapineMuscarinic acetylcholine receptor M1target
DB00363ClozapineMuscarinic acetylcholine receptor M2target
DB00363ClozapineMuscarinic acetylcholine receptor M3target
DB00363ClozapineMuscarinic acetylcholine receptor M4target
DB00363ClozapineMuscarinic acetylcholine receptor M5target
DB00363Clozapine5-hydroxytryptamine receptor 1Btarget
DB00363Clozapine5-hydroxytryptamine receptor 1Dtarget
DB00363Clozapine5-hydroxytryptamine receptor 1Etarget
DB00363Clozapine5-hydroxytryptamine receptor 3Atarget
DB00363Clozapine5-hydroxytryptamine receptor 6target
DB00363Clozapine5-hydroxytryptamine receptor 7target
DB00363ClozapineAlpha-1A adrenergic receptortarget
DB00363ClozapineAlpha-1B adrenergic receptortarget
DB00363ClozapineAlpha-2A adrenergic receptortarget
DB00363ClozapineAlpha-2B adrenergic receptortarget
DB00363ClozapineAlpha-2C adrenergic receptortarget
DB00363ClozapineCytochrome P450 2C9enzyme
DB00363ClozapineMultidrug resistance protein 1transporter
DB00363ClozapineCytochrome P450 3A4enzyme
DB00363ClozapineCytochrome P450 2C19enzyme
DB00363ClozapineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00363ClozapineUDP-glucuronosyltransferase 1-4enzyme
DB00363ClozapineCytochrome P450 1A1enzyme
DB00363ClozapineCytochrome P450 1B1enzyme
DB00363ClozapineCytochrome P450 2A6enzyme
DB00363ClozapineCytochrome P450 2C8enzyme
DB00363ClozapineCytochrome P450 2E1enzyme
DB00363ClozapineGlutathione S-transferase Ptarget
DB01075DiphenhydramineHistamine H1 receptortarget
DB01075DiphenhydramineCytochrome P450 2D6enzyme
DB01075DiphenhydramineCytochrome P450 1A2enzyme
DB01075DiphenhydramineCytochrome P450 2C9enzyme
DB01075DiphenhydramineCytochrome P450 2C19enzyme
DB01075DiphenhydramineCytochrome P450 2C18enzyme
DB01075DiphenhydramineCytochrome P450 2B6enzyme
DB01075DiphenhydramineSolute carrier family 22 member 2transporter
DB01075DiphenhydramineSolute carrier family 22 member 1transporter
DB01075DiphenhydramineSolute carrier family 22 member 5transporter
DB01075DiphenhydramineProstaglandin G/H synthase 1enzyme
DB01075DiphenhydramineMuscarinic acetylcholine receptor M2target
DB00387ProcyclidineMuscarinic acetylcholine receptor M1target
DB00387ProcyclidineMuscarinic acetylcholine receptor M2target
DB00387ProcyclidineMuscarinic acetylcholine receptor M4target
DB00387ProcyclidineMuscarinic acetylcholine receptor M3target
DrugDrug NamePhaseStatusCount
DB00248CabergolineNot AvailableCompleted1
DB00190CarbidopaNot AvailableCompleted1
DB01235LevodopaNot AvailableCompleted1